BR112016003868A8 - Método, aparelho, mídia de armazenamento não transitório, e, programa de computador - Google Patents
Método, aparelho, mídia de armazenamento não transitório, e, programa de computadorInfo
- Publication number
- BR112016003868A8 BR112016003868A8 BR112016003868A BR112016003868A BR112016003868A8 BR 112016003868 A8 BR112016003868 A8 BR 112016003868A8 BR 112016003868 A BR112016003868 A BR 112016003868A BR 112016003868 A BR112016003868 A BR 112016003868A BR 112016003868 A8 BR112016003868 A8 BR 112016003868A8
- Authority
- BR
- Brazil
- Prior art keywords
- computer program
- perform
- trainer
- storage media
- tissue
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 238000004590 computer program Methods 0.000 title abstract 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 210000001124 body fluid Anatomy 0.000 abstract 2
- 239000010839 body fluid Substances 0.000 abstract 2
- 230000005754 cellular signaling Effects 0.000 abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C99/00—Subject matter not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Computing Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Algebra (AREA)
- General Physics & Mathematics (AREA)
- Mathematical Analysis (AREA)
- Mathematical Optimization (AREA)
- Mathematical Physics (AREA)
- Pure & Applied Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
MÉTODO, APARELHO, MÍDIA DE ARMAZENAMENTO NÃO TRANSITÓRIO, E, PROGRAMA DE COMPUTADOR. A presente invenção refere-se a um método que compreende inferir a atividade de uma via de sinalização celular PI3K em um tecido e/ou em células e/ou em um fluido corpóreo de um paciente, com base ao menos nos níveis de expressão de um ou mais genes-alvo da via de sinalização celular PI3K medidos em uma amostra extraída do tecido e/ou das células e/ou do fluido corpóreo do paciente. A presente invenção refere-se, adicionalmente, a um aparelho que compreende um processador digital configurado para executar esse tipo de método, a uma mídia de armazenamento não transitório que armazena instruções que são executáveis por um dispositivo de processamento digital para executar esse tipo de método, e a um programa de computador que compreende meios de código de programa para fazer com que um dispositivo de processamento digital execute esse tipo de método.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14150145 | 2014-01-03 | ||
PCT/EP2014/079468 WO2015101635A1 (en) | 2014-01-03 | 2014-12-30 | Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression. |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016003868A2 BR112016003868A2 (pt) | 2017-12-05 |
BR112016003868A8 true BR112016003868A8 (pt) | 2022-11-08 |
Family
ID=49920140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016003868A BR112016003868A8 (pt) | 2014-01-03 | 2014-12-30 | Método, aparelho, mídia de armazenamento não transitório, e, programa de computador |
Country Status (10)
Country | Link |
---|---|
US (2) | US11261495B2 (pt) |
EP (1) | EP3013986B1 (pt) |
JP (1) | JP6077178B2 (pt) |
CN (2) | CN112795650A (pt) |
AU (1) | AU2014375206B2 (pt) |
BR (1) | BR112016003868A8 (pt) |
CA (1) | CA2923092C (pt) |
DK (1) | DK3013986T3 (pt) |
ES (1) | ES2613521T3 (pt) |
WO (1) | WO2015101635A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7065610B6 (ja) | 2014-10-24 | 2022-06-06 | コーニンクレッカ フィリップス エヌ ヴェ | 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測 |
JP7065609B6 (ja) | 2014-10-24 | 2022-06-06 | コーニンクレッカ フィリップス エヌ ヴェ | 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測 |
WO2016062891A1 (en) | 2014-10-24 | 2016-04-28 | Koninklijke Philips N.V. | ASSESSMENT OF TGF-β CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION |
ES2861400T3 (es) | 2015-08-14 | 2021-10-06 | Koninklijke Philips Nv | Evaluación de la actividad de la ruta de señalización celular de NFkB usando modelos matemáticos de la expresión de genes diana |
RU2019100441A (ru) * | 2016-06-13 | 2020-07-14 | Конинклейке Филипс Н.В. | Способ логического вывода об активности транскрипционного фактора пути сигнальной трансдукции у субъекта |
EP3763732A1 (en) | 2016-11-25 | 2021-01-13 | Koninklijke Philips N.V. | Method to distinguish tumor suppressive foxo activity from oxidative stress |
EP3431582A1 (en) | 2017-07-18 | 2019-01-23 | Koninklijke Philips N.V. | Cell culturing materials |
EP3462348A1 (en) | 2017-09-28 | 2019-04-03 | Koninklijke Philips N.V. | Bayesian inference |
JP7257405B2 (ja) * | 2017-10-02 | 2023-04-13 | コーニンクレッカ フィリップス エヌ ヴェ | 免疫細胞型及び免疫応答の機能状況の決定 |
EP3461915A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3502279A1 (en) * | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
US20210052875A1 (en) * | 2018-01-24 | 2021-02-25 | Thomas Jefferson University | Biodiffusion chamber |
EP3812474A1 (en) | 2019-10-22 | 2021-04-28 | Koninklijke Philips N.V. | Methods of prognosis in high-grade serous ovarian cancer |
CN113785075A (zh) | 2019-05-03 | 2021-12-10 | 皇家飞利浦有限公司 | 高级别浆液性卵巢癌的预后方法 |
EP3739588A1 (en) | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
EP3882363A1 (en) | 2020-03-17 | 2021-09-22 | Koninklijke Philips N.V. | Prognostic pathways for high risk sepsis patients |
EP3978628A1 (en) | 2020-10-01 | 2022-04-06 | Koninklijke Philips N.V. | Prognostic pathways for viral infections |
EP4136261A1 (en) | 2020-04-16 | 2023-02-22 | InnoSIGN B.V. | Prognostic pathways for viral infections |
EP3940704A1 (en) | 2020-07-14 | 2022-01-19 | Koninklijke Philips N.V. | Method for determining the differentiation state of a stem cell |
EP3960875A1 (en) | 2020-08-28 | 2022-03-02 | Koninklijke Philips N.V. | Pcr method and kit for determining pathway activity |
EP3965119A1 (en) | 2020-09-04 | 2022-03-09 | Koninklijke Philips N.V. | Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices |
EP3974540A1 (en) | 2020-09-25 | 2022-03-30 | Koninklijke Philips N.V. | Method for predicting immunotherapy resistance |
EP4015651A1 (en) | 2020-12-17 | 2022-06-22 | Koninklijke Philips N.V. | Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients |
EP4039825A1 (en) | 2021-02-09 | 2022-08-10 | Koninklijke Philips N.V. | Comparison and standardization of cell and tissue culture |
JP2024514404A (ja) | 2021-03-11 | 2024-04-02 | コーニンクレッカ フィリップス エヌ ヴェ | 高リスク敗血症患者のための予後経路 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1592791A2 (en) * | 2003-02-10 | 2005-11-09 | National Institute of Advanced Industrial Science and Technology | Regulation of gene expression by dna interference |
TW200920405A (en) * | 2007-08-24 | 2009-05-16 | Oncotherapy Science Inc | PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis |
WO2010009337A2 (en) * | 2008-07-16 | 2010-01-21 | Dana-Farber Cancer Institute, Inc. | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof |
RU2012148699A (ru) * | 2010-04-16 | 2014-05-27 | Дженентек, Инк. | Foxo3a как прогностический биомаркер для эффективности ингибитора пути киназы pi3k/акт |
EP2549399A1 (en) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
CN111961726A (zh) | 2012-12-26 | 2020-11-20 | 皇家飞利浦有限公司 | 使用靶基因表达的线性组合评价细胞信号传导途径活性 |
WO2014174003A1 (en) | 2013-04-26 | 2014-10-30 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities |
EP3461916A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression |
-
2014
- 2014-12-30 CA CA2923092A patent/CA2923092C/en active Active
- 2014-12-30 CN CN202110045252.6A patent/CN112795650A/zh active Pending
- 2014-12-30 AU AU2014375206A patent/AU2014375206B2/en active Active
- 2014-12-30 JP JP2016515946A patent/JP6077178B2/ja active Active
- 2014-12-30 US US15/023,820 patent/US11261495B2/en active Active
- 2014-12-30 DK DK14824498.1T patent/DK3013986T3/en active
- 2014-12-30 WO PCT/EP2014/079468 patent/WO2015101635A1/en active Application Filing
- 2014-12-30 EP EP14824498.1A patent/EP3013986B1/en active Active
- 2014-12-30 ES ES14824498.1T patent/ES2613521T3/es active Active
- 2014-12-30 BR BR112016003868A patent/BR112016003868A8/pt not_active Application Discontinuation
- 2014-12-30 CN CN201480048682.1A patent/CN105492630A/zh active Pending
-
2022
- 2022-01-17 US US17/577,078 patent/US20220259666A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2014375206A1 (en) | 2016-03-03 |
CN105492630A (zh) | 2016-04-13 |
JP6077178B2 (ja) | 2017-02-08 |
CA2923092A1 (en) | 2015-07-09 |
CA2923092C (en) | 2019-12-17 |
US11261495B2 (en) | 2022-03-01 |
BR112016003868A2 (pt) | 2017-12-05 |
JP2016536976A (ja) | 2016-12-01 |
ES2613521T3 (es) | 2017-05-24 |
AU2014375206B2 (en) | 2021-09-30 |
US20220259666A1 (en) | 2022-08-18 |
EP3013986B1 (en) | 2016-11-16 |
CN112795650A (zh) | 2021-05-14 |
WO2015101635A1 (en) | 2015-07-09 |
US20160298196A1 (en) | 2016-10-13 |
EP3013986A1 (en) | 2016-05-04 |
DK3013986T3 (en) | 2017-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016003868A8 (pt) | Método, aparelho, mídia de armazenamento não transitório, e, programa de computador | |
BR112015015131A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto | |
BR112018002848A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular | |
BR112014000965B8 (pt) | Método, aparelho e meio de armazenamento não transitório | |
BR112018008357A2 (pt) | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas | |
BR112019022538A8 (pt) | Técnicas para pareamento comportamental em um sistema de centro de contato | |
BR112017026709A2 (pt) | tratamento e diagnóstico de câncer | |
BR112017025045A2 (pt) | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 | |
GB2552267A (en) | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results | |
BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
BR112016020897A2 (pt) | ?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento? | |
BR112019010553A2 (pt) | método para inferir a atividade de uma via de sinalização celular pi3k em um indivíduo e programa de computador | |
WO2017116817A3 (en) | Testing of medicinal drugs and drug combinations | |
CY1123793T1 (el) | Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια | |
WO2014124339A3 (en) | Use of translational profiling to identify target molecules for therapeutic treatment | |
BR112018003238A2 (pt) | seleção de pacientes para terapia de combinação | |
WO2016130572A3 (en) | Methods of determining levels of exposure to radiation and uses thereof | |
BR112017014361A2 (pt) | métodos para aperfeiçoamento de terapia celular | |
BR112015030526A2 (pt) | detecção de aorta automatizada em um volume de tca | |
BR112016024143A2 (pt) | tratamento de câncer | |
BR112017022320A2 (pt) | métodos para tratamento de câncer de pulmão | |
BR112015017903A2 (pt) | vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
MX2017006959A (es) | Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable. | |
BR112017008805A2 (pt) | tratamento de córnea usando laminina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: INNOSIGN B.V. (NL) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |